NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis $2.59 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.54 -0.04 (-1.74%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Savara Stock (NASDAQ:SVRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Savara alerts:Sign Up Key Stats Today's Range$2.52▼$2.6250-Day Range$1.94▼$2.8452-Week Range$1.89▼$4.70Volume689,345 shsAverage Volume994,048 shsMarket Capitalization$447.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.60Consensus RatingModerate Buy Company Overview Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Read More Savara Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreSVRA MarketRank™: Savara scored higher than 30% of companies evaluated by MarketBeat, and ranked 780th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSavara has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 4 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.45) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Savara's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.67% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Savara has recently increased by 0.43%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.67% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Savara has recently increased by 0.43%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Savara this week, compared to 4 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,179.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.33% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address SVRA Stock News HeadlinesOppenheimer Assumes Coverage of Savara (SVRA) With an Outperform RatingAugust 1 at 3:51 AM | msn.comSavara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 25, 2025 | americanbankingnews.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)Savara: Repairing The Molbreevi aPAP Opportunity After RTFJuly 22, 2025 | seekingalpha.comSavara Announces New Employment Inducement GrantJuly 18, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJuly 6, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 27, 2025 | prnewswire.comSee More Headlines SVRA Stock Analysis - Frequently Asked Questions How have SVRA shares performed this year? Savara's stock was trading at $3.07 at the beginning of the year. Since then, SVRA shares have decreased by 15.6% and is now trading at $2.59. How were Savara's earnings last quarter? Savara Inc. (NASDAQ:SVRA) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). Who are Savara's major shareholders? Top institutional investors of Savara include Farther Finance Advisors LLC (0.02%), Teacher Retirement System of Texas (0.01%) and May Hill Capital LLC (0.01%). Insiders that own company stock include Rick Yang, David A Ramsay, Matthew Pauls, David L Lowrance, Joseph S Mccracken, Raymond Dennis Pratt, Richard J Hawkins and Nevan C Elam. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Southern First Bancshares (SFST) and TotalEnergies (TTE). Company Calendar Last Earnings5/13/2025Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876Employees20Year FoundedN/APrice Target and Rating Average Price Target for Savara$5.60 High Price Target$9.00 Low Price Target$2.00 Potential Upside/Downside+116.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-65.88% Return on Assets-52.35% Debt Debt-to-Equity Ratio0.20 Current Ratio14.91 Quick Ratio14.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book2.59Miscellaneous Outstanding Shares172,840,000Free Float163,625,000Market Cap$447.66 million OptionableOptionable Beta0.40 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SVRA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.